– NETHERLANDS, Amsterdam – Scenic Biotech, a pioneer in the field of modifier therapies for severe diseases, today announced the appointment of Ben Machielse to its Board of Directors, bringing over 25 years of experience in the biotech industry with proven expertise in leading the development of therapeutics through clinical evaluation up to market approval in start-ups and fully integrated companies.
Ben Machielse will replace Sandra Glucksmann, who is stepping down from the Board.
“Ben’s extensive experience across all stages of drug development and for rare disease indications, including Niemann-Pick Disease, will be instrumental in our next phase of growth,” said CEO Oscar Izeboud. “Together with Ben, we are well positioned to materialize on Scenic’s potential to rebalance health by neutralizing disease impact with our pipeline of modifier therapies.”
About Ben Machielse
Ben Machielse brings deep experience in guiding life sciences companies through the development and regulatory approval of new therapeutics. He served as CEO of Vtesse, a rare disease company dedicated to developing treatments for Niemann-Pick Disease, where he built the company, and oversaw the completion of the pivotal study and the subsequent acquisition by Sucampo Pharmaceuticals in April 2017. Before this, Ben Machielse served as COO of Omthera Pharmaceuticals, where he led the development and approval of a drug for the treatment of hypertriglyceridemia. His contributions were instrumental in Omthera’s IPO and eventual acquisition by AstraZeneca. He was also EVP of Operations at MedImmune, where he spent 11 years leading the global development and operations of therapeutic antibodies, small molecules, and vaccine products. Before his tenure at MedImmune, Ben Machielse held executive positions in product development, quality, and operations at Xoma Corporation and Centocor BV. Currently, he serves as the chairman of the board at Mosanna Therapeutics and has held board positions at Polyneuron Pharmaceuticals, Xencor, Tetragenetics, Comet Therapeutics, and Complexa.
“Scenic’s pioneering approach, fueled by its unique Cell-Seq platform, is opening unprecedented avenues to map previously unexplored biological pathways and investigate the complexities of disease biology in genetic disorders,” said Ben Machielse. “I look forward to supporting the Scenic team in navigating the path from discovery through therapeutic development, ensuring that their innovative treatments reach patients in need.”
Ben Machielse holds a Bachelor of Science in Medical Biology and a Master’s in Biochemistry from the University of Utrecht in the Netherlands.
About Scenic Biotech
Scenic Biotech is advancing modifier therapy, a radically new approach to treating genetic disorders. Instead of targeting the primary disease-causing mutation, modifier therapy seeks to rebalance health by acting on another function in the genome that can neutralize the disease impact, leading to a therapeutic effect. Our robust pipeline, derived from our proprietary Cell-Seq platform, includes first-in-class small molecule programs that are either wholly owned or partnered through strategic collaborations with multinational pharmaceutical leaders. By unlocking new pathways in the genome, Scenic will develop a range of modifier therapies to help patients.
For more: https://scenicbiotech.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.